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Abstract
Background: Metformin is a drug commonly used in individuals with type 2 dia-
betes, obesity, and impaired glucose tolerance. It has a strong safety profile in both 
children and adults. Studies utilizing the Drosophila model and knock out mouse 
model of fragile X syndrome (FXS) have found metformin to rescue memory, social 
novelty deficits, and neuroanatomical abnormalities. These studies provided prelimi-
nary evidence that metformin could be used as a targeted treatment for the cognitive 
and behavioral problems associated with FXS. Previously, a case series of children 
and adults with FXS treated with metformin demonstrated improvements in irritabil-
ity, social responsiveness, language, and hyperactivity.
Methods: Here, we present nine children with FXS between 2 and 7 years of age who were 
treated clinically with metformin and monitored for behavioral and metabolic changes.
Results: Parent reports and developmental testing before and after metformin are 
presented. There were improvements in language development and behavior (such 
as lethargy and stereotypy) in most of the patients.
Conclusion: These results support the need for a controlled trial of metformin in 
children with FXS under 7 years old whose brains are in a critical developmental 
window and thus may experience a greater degree of clinical benefit from metformin.
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1 |  INTRODUCTION
Fragile X syndrome (FXS) is the most common inherited 
form of intellectual disability (ID) and is typically diag-
nosed between 2 and 3  years of age at the time language 
delays and behavioral manifestations emerge (Bailey, Cody 
Hazlett, Roberts, & Wheeler, 2011). It is caused by a trinu-
cleotide repeat expansion of CGG in the promoter region of 
Fragile X Mental Retardation‐1 (FMR1, OMIM: 309550) 
gene, leading to methylation, transcriptional silencing, and 
the absence or deficiency of fragile X mental retardation 
protein (FMRP).
Metformin was originally FDA‐approved for its effects in 
lowering blood glucose levels in patients with type 2 diabetes 
(T2D). It is safe and effective at doses up to 1,000 mg twice a 
day in children 10–16 years old with T2D (Jones, Arslanian, 
Peterokova, Park, & Tomlinson, 2002). Because its mecha-
nism of action does not directly stimulate insulin, metformin 
is unlikely to lead to hypoglycemic episodes (Bodmer, 
Meier, Krahenbuhl, Jick, & Meier, 2008; Bolen, Feldman, 
Vassy, &, Feldman, & Vassy&&, 22007). Metformin has 
since expanded to the treatment of obesity and overeating 
in children and adults with and without T2D (Anagnostou 
et al., 2016; Klein, Cottingham, Sorter, Barton, & Morrison, 
2006; Muzar, Lozano, Kolevzon, & Hagerman, 2016; Park, 
Kinra, Ward, White, & Viner, 2009). For patients who are 
nonobese, metformin has been effective in glycemic con-
trol (Ong, Molyneaux, Constantino, Twigg, & Yue, 2006). 
In FXS, overeating is commonly associated with psychiatric 
comorbidities including anxiety and obsessive‐compulsive 
behaviors. Also, the Prader‐Willi‐phenotype (PWP) of FXS 
is found in less than 10% of children with FXS. The FXS‐
PWP is associated with hyperphagia, morbid obesity, delayed 
puberty, and lowered cytoplasmic FMRP interacting protein 
(CYFIP1, OMIM: 606322) expression (Muzar et al., 2016; 
Nowicki et al., 2007). The common use of atypical antipsy-
chotics in children with FXS further increases their risk for 
obesity. Treatment with metformin showed clinical improve-
ment in eating behaviors and weight loss in those with and 
without FXS‐PWP and is now recommended for the treat-
ment of obesity in FXS (Dy et al., 2018).
Recent research in animal models of FXS has demon-
strated that metformin, a T2D medication, can rescue both 
behavioral and cognitive features of FXS. In the Drosophila 
FXS model, metformin rescued abnormalities of circadian 
rhythm and memory problems (Monyak et al., 2017). In 
the FMR1 knock out (KO) mouse, metformin rescued many 
deficits including: social deficits, seizures, macroorchidism, 
and was also seen to improve extracellular signal regulated 
kinase (ERK) signaling, eukaryotic translation initiation fac-
tor 4e (EIF4E, OMIM: 133440) phosphorylation, and matrix 
metalloproteinase 9 (MMP9, OMIM: 120361) overexpres-
sion (Esfahanian et al., 2012; Gantois et al., 2017; Gantois, 
Popic, Khoutorsky, & Sonenberg, 2018). Upregulation of 
MMP9 has been shown to interfere with synaptic maturation 
and plasticity in both the FMR1 KO mouse (Bilousova et al., 
2009; Rotschafer, Trujillo, Dansie, Ethell, & Razak, 2012) 
and in patients with FXS (AlOlaby et al., 2017; Dziembowska 
& Wlodarczyk, 2012). Metformin has been shown to lower 
MMP9 levels via reduction of EIF4E phosphorylation which 
promotes translation of a subset of mRNAs including MMP9 
(Gantois et al., 2017, 2018; Hoeffer et al., 2012; Li et al., 
2017; Muzar et al., 2016). These developments have led to the 
off‐label clinical use of metformin in patients with FXS. The 
first seven cases of patients ages 4–60 years old treated clin-
ically demonstrated improvements on the Aberrant Behavior 
Checklist‐Community (ABC‐C), language, and conversa-
tional skills per parent report (Dy et al., 2018). The growing 
interest of metformin as a feasible alternative for this popu-
lation led to the initiation of a controlled trial of metformin 
for individuals with FXS between the ages of 6–25 years old 
(NCT03479476). In addition, a smaller open label trial of 
metformin is also underway for those 10–40 years old with 
FXS (NCT03722290).
Previous studies have suggested that targeted treatments 
may work best for young children with FXS (Berry‐Kravis 
et al., 2017; Greiss Hess et al., 2016; Leigh et al., 2013). 
Furthermore, recent research in the FMR1 KO mouse shows 
that correction of key disruptions in neuronal development 
during the critical period in young animals results in res-
toration of synaptic development, produces a long‐lasting 
rescue of somatosensory circuit function, and normalizes 
differentially expressed proteins (He et al., 2017). Such find-
ings indicate a critical period of development during which 
targeted interventions may have significant and durable ef-
fects on developmental trajectory and outcomes in FXS. 
These data suggest that metformin would have a significant 
benefit in young children with FXS; here we describe nine 
boys between 2 and 7  years old with FXS who underwent 
off‐label clinical treatment with metformin for a period of at 
least 3 months. It is important to emphasize that represented 
here are individual cases of young children with FXS treated 
clinically with metformin, not an open‐label trial; therefore, 
there is no specified protocol homogenizing the sample.
2 |  MATERIALS AND METHODS
Patients were seen clinically at the Fragile X Treatment and 
Research Center at the MIND Institute at the University of 
California, Davis Health for management of FXS. All patients 
had a full mutation FXS documented via FMR1 (GenBank: 
NG_007529.2) DNA testing. Laboratory studies were at-
tempted pre‐ treatment whenever possible and included fast-
ing glucose, a chemistry panel, and HbA1c. When available, 
copies of previous FXS testing, including FMR1 methylation 
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status, were also obtained from caregivers or patient records 
with permission. Post‐treatment laboratory studies were 
collected in many cases at patients’ primary care locations 
and were therefore not available to report here. All families 
signed an institutional review board‐approved consent form 
for research involving the blood work and developmental 
testing and gave consent for publication of their clinical case 
histories.
Parents completed the ABC‐C and reported on behav-
ior and symptoms pre‐ and post‐metformin treatment. The 
ABC‐C was scored using the FXS algorithm (Sansone et 
al., 2012). The ABC‐C is a 58‐item global behavior check-
list implemented for the measurement of treatment effects in 
individuals with ID; a factor analysis of the ABC‐C specifi-
cally in FXS generated a 6‐factor structure: irritability, leth-
argy, stereotypy, hyperactivity, inappropriate speech, and 
social avoidance (Berry‐Kravis et al., 2017). Higher sub-
scale scores are correlated with more severe aberrant behav-
ior; therefore, a decrease in the scores across each domain 
is indicative of an improvement of that behavior. Length of 
time between pre‐ and post‐treatment ABC‐C administra-
tion ranged from 1 to 7 months due to the natural variability 
in duration of clinical follow‐up and caregiver report.
Developmental testing was administered pre‐ and post‐
treatment for six of the nine subjects using the Mullen scales 
of early learning (MSEL) (Mullen, 1995). The MSEL in-
cludes four domains: fine motor, receptive language, expres-
sive language, and visual reception, all of which have age 
equivalent scores generated. In place of the early learning 
composite (ELC) score, which is an age‐normed standard 
score generated from the aforementioned domains, a global 
development age (GDA) score was used. The GDA averages 
the age equivalents across the four domains (Roberts et al., 
2009) and thus provides a consistent metric that can be uti-
lized as a measurement for improvement in this report. For 
one of the subjects, pre‐treatment age equivalent scores from 
three of the four domains from the Bayley Scales of Infant 
and Toddler Development (Bayley, 2006) were used in place 
of pre‐treatment MSEL data, which was not available. The 
moderate correlation between the two developmental tests 
is reported in the MSEL test manual (Farmer, Golden, & 
Thurm, 2016; Mullen, 1995). Due to the clinical nature of 
this study, there is variability in the pre‐ and post‐testing time 
points for the MSEL among the cases which ranges from 7 to 
26 months after pre‐treatment testing.
Statistical analyses of pre‐ and post‐treatment ABC‐C 
and developmental testing scores are presented in median 
and interquartile ranges. They were done in Stata 14 utiliz-
ing a nonparametric test “signrank.” Stata command tests 
the equality of matched pairs of observations by using the 
Wilcoxon matched‐pairs signed‐ranks test and generates p‐
values (Wilcoxon, 1945). The null hypothesis is that both 
distributions are the same. A pre‐specified significance 
level of p <  .05 was assumed. Additionally, using MSEL 
age equivalent scores, mean linear slopes in all subscales 
and GDA were generated using the individual trajectories 
per patient. The slope was then compared to m = 0.48, the 
experimentally determined expected rate of developmen-
tal gains seen in children with FXS (Bailey Jr., Hatton, & 
Skinner, 1998).
3 |  RESULTS
3.1 | Case 1
Patient 1 is a 4‐year, 2‐month‐old boy diagnosed with FXS 
at 9 months of age due to missed motor milestones and de-
layed babbling. He was adopted at birth and lives with his 
adoptive family. His birth weight was 3.6 kg and he had res-
piratory distress requiring immediate treatment. He was diag-
nosed with neonatal pneumonia, requiring a 7‐day Neonatal 
Intensive Care Unit stay. He sat alone at 8 months and took 
steps at 13 months. With the intention of improving speech, 
at 12  months he was started on sertraline but with limited 
results; his first words were spoken at 16 months, with very 
slow progress in language thereafter. He had tympanostomy 
tubes placed at age 2 without significant improvement in 
language. He has a history of awakening multiple times per 
night for a total of 2–4  hr. Behaviorally, he is generally a 
“happy and social child with mild anxiety.”
On examination at age 2 years, typical physical features 
of FXS were observed, and baseline laboratory findings were 
normal (see Table 1). He was started on metformin at 25 mg 
of the liquid form that is 100 mg/ml at dinner, and his dose 
was gradually increased to 200  mg twice a day (bid) over 
1 year (see Table 1). After initiation of metformin, his sleep 
disturbance resolved, only occasionally awakening once for 
roughly 30  min. Two weeks after initiation, he went from 
stacking 3–4 blocks to stacking a tower of 11 or more blocks; 
within a few more weeks, he began building more complex 
structures comprised of different size blocks. He showed 
marked improvement in self‐help and motor activities, in-
cluding toilet training, clearing the table and loading the 
dishwasher, brushing his own teeth, dressing independently, 
and learning how to make toast. His preschool teachers, who 
were unaware of metformin treatment, told his mother that 
“it's like something just clicked or he just woke up. He's a 
whole different kid.”
Patient 1’s ABC‐C composite score improved on met-
formin (see Table 2). With respect to language acquisition, he 
had 10–20 verbal words and 20 signs at the time of initiation. 
Six months later, he demonstrated use of 60–80 words, in-
cluding several 2‐word phrases and 100 signs, and his mother 
reports that his cognitive skills have significantly improved 
as well. He tolerated all medication increases with only minor 
self‐limited diarrhea for 1–2 days. Fasting blood glucose has 
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remained stable at all doses. He is tolerating his current dose 
without problems.
3.2 | Case 2
Patient 2 is a 6‐year, 1‐month‐old boy diagnosed with FXS 
at the age of 2 years 7 months after parental concern regard-
ing developmental delays. He was born at term and weighed 
3.2 kg. He sat alone at 9 months, walked at 19 months, and 
fed himself and said his first word at 3 years. Past medical 
history includes reflux since infancy as well as more than 
10 episodes of acute otitis media (OM), prompting place-
ment of his first set of pressure equalization (PE) tubes at 
3 years, 11 months. After a possible seizure at 7 months, 
patient 2’s EEG and MRI were normal; no further seizure‐
like episodes have occurred since. Once his parents noted 
loud snoring and brief pauses in breathing, a diagnosis of 
obstructive and central sleep apnea was made and an ad-
enoidectomy was performed.
Behaviorally, patient 2 chews on things, babbles to him-
self, and hand flaps when he is excited or anxious. His eye 
contact is poor with his peers but better with adults; he is 
hyperactive and engages in perseverative behavior, such as 
repetitively pouring liquids.
After diagnosis, patient 2 was evaluated for an individ-
ualized education program and started school where he is 
receiving speech, occupational, and physical therapy. At 
4 years, he initiated metformin at a dose of 50 mg bid which 
was gradually increased to 100  mg bid (see Table 1). His 
pre‐ and post‐metformin ABC‐C scores demonstrate an 
overall decrease across all measured behaviors (see Table 
2). Since starting metformin, he has also made progress in 
expressive language, specifically in expanding his vocabu-
lary. Although baseline MSEL testing was not available for 
comparison, a post‐treatment MSEL at 58 months yielded 
age equivalent scores (in months) of 25 for visual recep-
tion, 27 for fine motor, 18 for receptive language, and 15 
for expressive language, with an ELC of 49. His parents re-
ported no significant side effects aside from loose stools, 
which resolved spontaneously within two days of metformin 
initiation.
3.3 | Case 3
Patient 3 is an 8‐year, 6‐month‐old boy with a normal birth 
history. However, significant developmental delays and hy-
potonia led to a FXS diagnosis at 18 months. Due to severe 
anxiety, at 3.5 years he was treated with sertraline, which was 
beneficial. Attention deficit hyperactivity disorder symptoms 
emerged at 3  years, and he began guanfacine a year later. 
The stimulant methylphenidate was introduced at 5  years 
with beneficial effects on hyperactivity and short attention 
span. Past medical history includes intermittent exotropia TA
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and mild astigmatism, two episodes of OM, and occasional 
constipation. He currently receives physical, occupational, 
and speech‐language therapy.
At the age of 6 years, 7 months, patient 3 initiated met-
formin at a starting dose of 50 mg at dinner and increased to 
50 mg bid without any side effects (see Table 1). He experi-
enced initial improvement in behavior, but after one month 
he suffered a generalized seizure in the early morning with 
tonic‐clonic movements and was taken to the ER. An MRI 
revealed grey matter heterotopias and a possible cortical ab-
normality of the posterior cingulate gyrus; furthermore, an 
EEG showed spike wave discharges that were diffusely dis-
persed throughout the reading. ER laboratory reports showed 
a normal glucose. At this time, he was started on oxcarba-
zepine for treatment of his seizures. Due to the occurrence 
of a second generalized seizure 1 week later, metformin was 
discontinued.
Patient 3 exhibited an overall improvement across all 
measurements on the ABC‐C before metformin discontinu-
ation (see Table 2). Likewise, developmental testing shows 
an overall improvement pre‐ and post‐metformin (see Table 
3). Within the first month of his treatment with metformin, 
patient 3’s parents reported gains in his language and cogni-
tion; specifically, his mother noted more complex language, 
thoughts, and statements from him. One year later, he contin-
ues on oxcarbazepine without seizures.
3.4 | Case 4
Patient 4 is a 6‐year‐old boy born via emergency C‐section 
due to premature labor at 33  weeks gestation; his mother 
had partial placental abruption. Developmentally he sat at 
6.5 months, crawled at 12 months, walked at 12.5 months, 
and began speaking at 3 years. Patient 4 exhibits some hand 
flapping when excited, tactile defensiveness, and anxiety in 
new situations. Past medical history includes recurrent OM 
treated with PE tube placement, gastroesophageal reflux 
disease (GERD), milk intolerance, chronic rhinitis, partial 
adenoidectomy, and two episodes each of bronchiolitis and 
croup before 12 months.
Patient 4 began metformin at 4 years, 1 month (see Table 
1). His pre‐treatment MSEL was performed at a chronolog-
ical age of 39 months and yielded age equivalent scores (in 
months) of 23 for visual reception, 24 for fine motor, 28 for 
receptive language, and 14 for expressive language, with an 
ELC of 54. Follow‐up testing post‐treatment was not obtained. 
Since initiating metformin, his vocabulary has increased from 
2 words to about 40 words. His mother notes improvement in 
gross motor function, particularly proprioception and ability 
to imitate actions on command. She reports that metformin 
treatment has “unlocked” him, noting “he now has a general 
increased connectedness to [family] and others around him 
that he didn't have before.” His creative and independent play TA
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have soared, and he is now initiating play with his brother and 
dogs. Mother attributes these gains to metformin because of 
minimal to no therapy since initiation, aside from continu-
ing to attend his ongoing applied behavior analysis (ABA) 
sessions.
Patient 4's only reported side effect is increased verbaliza-
tion of frustration when he does not get his way. Indeed, on 
the ABC‐C, he exhibited a slight increase in irritability but an 
overall decrease across all other behaviors except stereotypy, 
which remained constant (see Table 2).
3.5 | Case 5
Patient 5 is an 9‐year, 3‐month‐old boy who was diagnosed 
at 2 years with FXS. Mother had a normal pregnancy until 
41  weeks when an emergency C‐section was performed 
for fetal distress. At 3 months, patient 5 underwent surgery 
for the repair of cleft lip and recovered well. He crawled at 
10 months, walked at 18 months, and spoke a few words at 
2  years; however, emergence of more words was delayed 
until approximately 5 years, with phrasing at 6 years. Due 
to recurrent OM, PE tubes were placed at 2 years and again 
at 4 years. He has also been diagnosed with autism spectrum 
disorder (ASD).
At 5 years old he was found seizing in his bedroom with 
a grand mal seizure. For several days afterwards, he was less 
verbal and off balance but he gradually recovered. An MRI 
at the time showed mildly dilated ventricles with a somewhat 
thin corpus callosum, and an EEG demonstrated right‐sided 
slowing and spike wave discharges. He began levetiracetam but 
discontinued due to increased aggression and other behavioral 
problems and instead started oxcarbazepine. On oxcarbaze-
pine, patient 5 continued to have staring spells that were often 
associated with projectile emesis and falling to the ground; 
these partial motor seizures occurred once or twice a week.
Behaviorally, patient 5 was very aggressive, hitting his 
parents and his grandparents. He had echolalia and sensitiv-
ity to noises and touch, and he engaged in both hand flapping 
and hand biting. Overall, he was very hyperactive, persever-
ative, and anxious.
At 7 years, patient 5 started metformin at a dose of 500 mg 
at dinner and increased to 500  mg bid a few months later 
(see Table 1). His pre‐treatment MSEL was performed at a 
chronological age of 93 months and yielded age equivalent 
scores (in months) of 27 for visual reception, 20 for fine 
motor, 23 for receptive language, and 18 for expressive lan-
guage, with an ELC of 49. Follow‐up testing post‐treatment 
was not yet obtained. Since initiation of metformin, he has 
not experienced any seizures or seizure‐like symptoms. He 
is now able to eat at normal frequencies rather than contin-
uously throughout the day. Behaviorally, his parents report 
improvement in irritability, hyperactivity, anxiety, tantrums, 
and aggression. His communication has also improved to the 
extent that he is now able to engage in a two‐way conver-
sation with multiple exchanges. Previously, his mother had 
constant complaints from school teachers about his behavior, 
but after metformin initiation she has received consistently 
positive feedback. The only side effect he has experienced is 
intermittent loose stools.
3.6 | Case 6
Patient 6 is a 5‐year, 4‐month‐old boy born via C‐section 
due to breech presentation at 35 weeks and weighing 2.6 kg. 
He had mild jaundice and was treated with phototherapy for 
12 hr before being discharged 4 days later. Past medical his-
tory includes reflux treated with omeprazole in the first year. 
He sat at 9 months, never crawled, and walked at 15 months. 
He said his first words at 24 months and when seen pre‐treat-
ment at 34 months he could combine 2 words (see Table 3). 
At 47 months, he was diagnosed with ASD.
Patient 6’s behavior at 34  months included excessive 
chewing, shyness, perseveration, hyperactivity, and a short 
attention span. He had mild sleeping problems and occa-
sional tantrums but was not aggressive. Ongoing interven-
tions included ABA, speech and language, in home, and 
physical therapy.
Patient 6 was started on metformin at an initial dose of 
50 mg at dinner and then increased to bid after 1 week (see 
Table 1). Although his initial response to metformin was pos-
itive (see Table 2), after 4 months increased hyperactivity and 
anxiety, decreased attention, and language regression were 
observed. Metformin was discontinued and the aforemen-
tioned problems subsequently resolved.
3.7 | Case 7
Patient 7 is a 3‐year, 11‐month‐old boy diagnosed with FXS 
at 16 months due to delayed communication milestones and 
a positive family history (see Table 1). He was born at term 
via normal spontaneous delivery without complications and 
weighed 4.6 kg. He sat independently at 6 months, took his 
first steps at 14.5 months, and said his first word at 15 months. 
At 15  months a diagnosis of Global Developmental Delay 
was made. At 20 months patient 7 was started on sertraline, 
and parents observed some improvement in self‐regulation 
and a reduction in separation anxiety (see Table 1).
Behaviorally, patient 7 is a social child who arm‐flaps 
when excited. He experiences mild to moderate separation 
and performance anxiety. He has significant verbal and non-
verbal communication delays and difficulty with imitation. 
Prior to metformin initiation, he could express himself using 
3–5 verbal words and 15 signs, and he stacked approximately 
3–4 blocks.
At 26  months patient 7 started taking 50  mg of met-
formin bid, and over the following 5 months his dose was 
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gradually increased up to 150  mg bid. Over time he has 
shown dose‐dependent improvement across multiple areas 
of development, including language acquisition (see Table 
3). Six months after initiation, he demonstrated use of 30 
verbal words and 25–30 signs, including some combina-
tions of 2–3 words and signs together. His therapists have 
noted improvements in his sustained attention, listening, 
focus, ability to imitate, and the speed with which he learns 
new words and signs. He is now stacking interlocking 
blocks greater than 15, and his family reports increased 
engagement in pretend play. He more regularly performs 
self‐help activities and daily tasks, such as dressing him-
self, picking up toys, throwing away trash, putting his 
dirty clothes in the hamper, and independently washing his 
hands. Behaviorally, his family has noted a significant in-
crease in hyperactivity and impulsivity over the last four 
months, the former of which is reflected in his ABC‐C 
composite scores (see Table 2).
Overall, patient 7 tolerated all metformin dose increases 
fairly well. Besides the increase in hyperactivity and impul-
sivity, his only side effect was an increase in frequency of 
nightly awakenings upon initiation and with each subsequent 
increase in dose, but sleep returned to normal within 2 weeks 
each time.
3.8 | Case 8
Patient 8 is a 5‐year, 7‐month‐old who boy was diagnosed 
with FXS at 22  months. His mother had a normal preg-
nancy, but delivery via C‐section was delayed 1 week due 
to lack of progression. At birth he weighed 3.8 kg and was 
tongue‐tied; his tongue was clipped the next day with-
out sequelae. He sat independently at 6  months, crawled 
at 8  months, and walked independently at 9  months. 
Significant language delay and behaviors such as hand flap-
ping, poor eye contact, and tactile defensiveness prompted 
evaluation and ASD was diagnosed at 18 months. He sub-
sequently enrolled in an early intervention preschool with 
expertise in ASD, speech and language therapy, and occu-
pational therapy. He had reflux as an infant with significant 
vomiting and poor weight gain but since stabilizing on a 
paleo diet, he has had less reflux but still suffers occasional 
diet‐related constipation. He was started on sertraline at 
25 months with a positive response (see Table 1).
On examination at 3 years, he was hyperactive and impul-
sive, demonstrating poor eye contact. He could only verbal-
ize single words such as “bye‐bye” or 2‐word combinations 
such as “big dog” or “black dog” (see Table 3). His mother 
reported that he would play chase games with other children 
but would not socially interact with them.
At 46 months he started on metformin at 50 mg at din-
ner and increased to 50 mg bid after a few weeks; he tol-
erated the dose increase well. Initially, he had some soft 
stools but no diarrhea. He is no longer aggressive, although 
he continues to have poor eye contact, hand flapping, and 
biting. Since metformin initiation, he has been eating more 
and maintains a healthy weight. He exhibited an overall de-
crease across all measurements on the ABC‐C (see Table 
2) and no cognitive decline on follow‐up developmental 
testing (see Table 3).
3.9 | Case 9
Patient 9 is a 5‐year, 3‐month‐old boy born at term via C‐sec-
tion after a pregnancy complicated by gestational diabetes. 
His developmental milestones included sitting at 8 months, 
crawling at 13 months, and walking at 16 months. He was 
diagnosed with FXS at 26 months of age and started on ser-
traline with a positive response in language development 
(see Table 1). Behaviorally, patient 9 hand flaps when ex-
cited and occasionally bites his fingers. He is social, making 
good eye contact, and often complimenting others and ask-
ing questions. He can be inattentive and hyperactive at times. 
He exhibits tantrums, irritability, and aggression (sometimes 
hitting and pushing people or objects). Past medical history 
includes seasonal eczema and three episodes of OM with PE 
tubes placed at 2 years, which led to a dramatic improvement 
in his language. However, by 3 years his mother noticed an 
increase in dysfluency and stuttering.
He began metformin at 4 years, initially taking 50 mg at 
dinner and gradually increasing to 150 mg bid. Since initi-
ation, he has exhibited improved language development: 
increased vocabulary and he now uses full sentences and 
carries out reciprocal conversations. His mother reports that 
he more frequently attempts and succeeds at problem solv-
ing without looking to others for help. Furthermore, he has 
made progress in his social development and is more regu-
larly seeking interactions with his peers for longer periods of 
time. He has experienced some loose stools and occasionally 
complains of stomach aches, but he continues to have a good 
appetite and overall tolerates metformin well.
Patient 9’s follow‐up developmental testing reflects im-
provement across all areas but most notably expressive lan-
guage (see Table 3). His ABC‐C showed a decrease across all 
subscales except for inappropriate speech and social avoid-
ance, which remained static (Table 2).
3.10 | Statistical results
Statistical analysis on the ABC‐C pre‐ and post‐treatment 
for all nine cases yielded a statistically significant (p < .05) 
improvement in two of the six factors: lethargy and ste-
reotypy (Table 5). These findings differentiate this cohort 
from others in previous observational studies that saw an 
increase in these two factors over time (Hustyi, Hall, Jo, 
Lightbody, & Reiss, 2014). Analyses on the Mullen results 
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were performed for at least five of the nine cases; p‐val-
ues (p < .05) suggest a statistically significant effect in all 
subscales and the global developmental age. Additionally, 
for all patients with both pre‐ and post‐treatment develop-
mental testing data available, mean linear slope trajectories 
were calculated (Table 4). Among the MSEL subscales, the 
rate of growth for receptive and expressive language—0.56 
and 0.77, respectively, exceeded previously published lit-
erature estimating a rate of growth with 0.48 in this popu-
lation (Bailey Jr. et al., 1998); in a larger sample size, this 
finding might indicate accelerated gains that could be at-
tributable to metformin, but given the small sample size 
and noncontrolled nature of the treatment, no definitive 
conclusions can be drawn except that no regression was 
observed.
4 |  DISCUSSION
In this study, we describe nine cases of young children with 
FXS between the ages of 2–7 years who were treated clini-
cally with metformin with beneficial effects in language 
and some areas of aberrant behavior as measured by the 
ABC‐C, developmental testing, and parent reports (Tables 
2 and 3). As is common in this population, all children de-
scribed in this report were receiving interventions in the 
community or at school, including speech and language 
therapy, physical and occupational therapy, and special ed-
ucation support. Those with ASD were also receiving ABA.
In comparison to typically developing children (TDC), 
those with FXS have a significantly lower rate of development; 
because of this, their IQ is found to decrease over time (Wright‐
Talamante et al., 1996). This observation can be attributed to 
the lack of FMRP, which is essential for synaptic plasticity and 
cognitive development. Those with FXS have significant defi-
cits in abstract reasoning and higher symbolic language skills 
so the IQ decline increases in later childhood and adolescence; 
they neither lose skills nor regress but fall further behind 
TDC over time (Bailey Jr. et al., 1998; Hagerman et al., 1989; 
Hodapp et al., 1990; Lachiewicz, Gullion, Spiridigliozzi, & 
Aylsworth, 1987; Roberts et al., 2009). Although babies with 
FXS are usually quiet in the first year of life, behavioral prob-
lems including irritability, hyperactivity, and tantrums emerge 
in the second and third years of life, and sleep disturbances 
are common (Roberts, McCary, Shinkareva, & Bailey, 2016). 
Language is expected to improve somewhat in the early years 
even in those with FXS who have not received pharmacological 
or nonpharmacological intervention, but approximately 10% 
of children with FXS remain nonverbal by age 7 (Komesidou, 
Brady, Fleming, Esplund, & Warren, 2017).
Treatment of children younger than 6  years of age has 
the potential of improving brain development in the absence 
of FMRP by reversing the upregulation of the mTORC1 
and MEK‐ERK pathways and lowering the elevated MMP9 
levels that are deleterious to synaptic development in FXS. 
Cognitive impairment is universally seen in males with the 
methylated full mutation due to the complete lack of FMRP. 
Counteracting the negative effects due to the lack of FMRP 
early in development has the potential to reverse the protein 
upregulation seen early on in FXS and prevent cognitive defi-
cits before they are entrenched.
The parents of the children in this report were positive 
overall about metformin treatment; while there is a possibil-
ity that these impressions were due to a placebo response, 
per parent account there was demonstrated improvement in 
language acquisition rate and practical expressive ability. 
Parents noted gains not only in verbal and nonverbal com-
munication but also in problem solving, motor abilities, and 
daily living skills. Behaviorally, tantrums and aggression 
were generally decreased, and improvement was observed in 
overall aberrant behavior as measured by the ABC‐C pre‐ and 
post‐treatment. The clinical treatment of the children in this 
report is not dissimilar to an open label treatment, and there-
fore bias can be introduced since the caregivers know that 
their child is being treated with a medication considered to be 
a potential targeted treatment for FXS. Informant based ques-
tionnaires, such as the ABC‐C, can introduce such bias and 
recall effects. A potential possibility for the improvement in 
Mullen subscale Pre‐metformina Post‐metformina Slopea,b p‐value* 
Visual receptionc 30 (18–38) 40 (29–40) 0.52 .04
Fine motor 20 (18–26) 25 (21–27) 0.34 .02
Receptive language 27 (19–32) 34 (27–36) 0.56 .03
Expressive language 19 (16–22) 28 (17–48) 0.77 .02
Early learning composite score 61 (54–63) 61 (55–62) NA .5
Global developmental agec,d 30 (21.2–31.2) 34.2 (33.7–35.5) 0.52 .04
aAll values measured in median and interquartile range. 
bRate of Growth. 
cAnalysis with n = 5, all others were calculated with n = 6. 
dGlobal developmental age was calculated based on the average age equivalents of the Mullen subscales. 
*A pre‐specified significance level of p < .05 was assumed. 
T A B L E  4  Statistical Analysis of 
Mullen Scales of Early Learning
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scores is that increases in adaptive behavior with time along 
with the natural course of development may be responsible 
in part for decreases (or the perception thereof) in aberrant 
behavior; likewise, caregivers could be habituating to the 
severity of their child's behavior over time. Despite this, a 
longitudinal study with 124 children and adolescents with 
FXS demonstrated a significant decrease in hyperactivity 
and irritability over time (Hustyi et al., 2014). Not all chil-
dren demonstrated an improvement on metformin. One pa-
tient (Case 7) had an increase in hyperactivity several months 
after metformin initiation, though this behavioral observation 
improved after discontinuation of treatment, it may also be 
unrelated since increased hyperactivity is expected in the de-
velopmental course of FXS in the early years of life (Grefer, 
Flory, Cornish, Hatton, & Roberts, 2016).
Seizures are experienced by approximately 14% of male 
and 6% of female children with FXS and is often associated 
with a diagnosis of ASD. Seizures are more often partial, al-
though generalized tonic‐clonic seizures may occur. Common 
age of seizure onset is in young and mid‐childhood (Berry‐
Kravis et al., 2010). After one month on metformin, patient 
3 experienced a seizure and despite subsequent initiation of 
the anticonvulsant oxcarbazepine, within 1  week a second 
episode occurred. Patient 3's MRI after the first episode re-
vealed grey matter heterotopias, which have been previously 
reported in FXS (Moro et al., 2006) and likely constitute the 
cause of the seizures. Metformin was discontinued at the 
discretion of the attending physician; however, the only rec-
ognized association of metformin with the presentation of 
seizures and other neurological symptoms has been reported 
in those with vitamin B12 deficiency (Lee, Chang, Wu, 
Weng, & Chen, 2005; Naha, Dasari, Vivek, & Prabhu, 2012) 
that can be occasionally seen after treatment  for more than 
4 months (Langan & Goodbred, 2017). Patient 3’s complete 
blood count, comprehensive metabolic panel including blood 
glucose, and urinalysis results were unremarkable at baseline 
and at time of hospital discharge after the first episode of a 
seizure. Furthermore, no drug interaction is known to exist 
between metformin and oxcarbazepine.
Contrary to what was seen in patient 3, metformin has 
been reported as exhibiting beneficial effects in epilepsy 
such as decreasing seizure susceptibility, reducing seizure 
number and length, suppressing progression of seizures and 
ameliorating learning and memory impairments (Gantois et 
al., 2018; Mehrabi et al., 2018; Yang et al., 2017; Zhao et 
al., 2014). Metformin is also known to improve seizures in 
the mouse model of FXS (Gantois et al., 2017). Indeed, in 
one patient (Case 5) the partial motor seizures were improved 
with metformin. The most commonly reported side effect of 
treatment was self‐limited loose stools after initiation or sub-
sequent dose increases. Thus, it is necessary to start at a low 
dose and increase dosage gradually until a maximum toler-
ated dose is reached. While the nine patients presented in this 
report demonstrate relative safety, further studies regarding 
safety are warranted. Close monitoring is recommended to 
detect any adverse behavioral changes that may accompany 
dose modification so that treatment can be discontinued if 
needed. In addition, further studies of young children treated 
with metformin should include careful monitoring for possi-
ble seizures and hyperarousal.
The results of this preliminary clinical treatment of chil-
dren with FXS 2–7 years old indicate the potential of met-
formin as a targeted treatment for young patients with FXS 
as data suggests language and cognitive benefits with no 
regression.
5 |  LIMITATIONS
Even though certain p‐values may suggest statistical signifi-
cance, it is important to address the limitations of our pre-
liminary data. The material presented here are several clinical 
case reports, not an open‐label study, hence no specified pro-
tocol is used. This cohort was treated clinically so there is 
variability in the time points for data collection; therefore, it 
is difficult to differentiate between the influence of time on 
the effects of metformin seen and the natural developmen-
tal progression of each patient. The small number of patients 
is a limitation in terms of statistical analyses; the presented 
statistical values could be the result of a large random error. 
Therefore, interpretation of the results as definitively provid-
ing evidence of an effect when p  <  .05, or a lack thereof 
when p > .05, is not possible. While there are limitations to 
the conclusions which can be drawn from the data, there were 
positive effects seen while the patients were treated with 
metformin. Likewise, our findings support a biologically 
plausible hypothesis based on previous work by Gantois 
and colleagues (Gantois et al., 2017) where metformin was 
shown to improve outcomes among the FMR1 KO mouse 
model of FXS. Our preliminary data, although promising, 
suggests that only a controlled trial of metformin in young 
T A B L E  5  Statistical Analysis for Aberrant Behavior 
Checklist‐Community
ABC‐C domain Pre‐metformina Post‐metformina p‐value* 
Irritability 14 (8–29) 12 (6–19) .1
Lethargy 1 (0–11) 1 (0–4) .04
Stereotypy 4 (2–9) 4 (0–5) .01
Hyperactivity 17 (13–22) 13 (11–14) .07
Speech 3 (0–6) 2 (2–6) .6
Social avoidance 0 (0–2) 1 (0–1) .2
Composite score 33 (29–67) 39 (20–51) .06
Note: All calculations were done with an n = 9.
aAll values measured in median and interquartile range. 
*A pre‐specified significance level of p < .05. was assumed. 
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children (two and older) with FXS can ascertain the influence 
of the treatment in this population (Table 5). 
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